TARS
Tarsus Pharmaceuticals Inc
NASDAQ: TARS · HEALTHCARE · BIOTECHNOLOGY
$60.67
-2.29% today
Updated 2026-04-29
Market cap
$2.61B
P/E ratio
—
P/S ratio
5.78x
EPS (TTM)
$-1.59
Dividend yield
—
52W range
$39 – $85
Volume
0.6M
WallStSmart proprietary scores
32
out of 100
Grade: F
Strong Sell
Investment rating
8.0
Growth
A6.3
Quality
B2.0
Profitability
F4.0
Valuation
C4/9
Piotroski F-Score
Moderate
1.1
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →204 stocks currently score above 75
Price targets
Analyst target
$94.22
+55.30%
12-Month target
—
—
Intrinsic (DCF)
$45.01
Margin of safety
-45.28%
1 Strong Buy8 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Free cash flow $12.97M — positive
+ Revenue growth 128.40% QoQ
Risks
- Altman Z 1.14 — distress zone
- Thin margins at -14.70%
- 45.28% above intrinsic value
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $25.82M | $17.45M | $182.95M | $451.36M | $451.36M |
| Net income | $-62.09M | $-135.89M | $-115.55M | $-66.42M | $-8.37M |
| EPS | — | — | — | — | $-1.59 |
| Free cash flow | $-49.54M | $-123.00M | $-84.59M | $-22.31M | $12.97M |
| Profit margin | -240.51% | -778.89% | -63.16% | -14.72% | -14.70% |
Peer comparison
Smart narrative
Tarsus Pharmaceuticals Inc trades at $60.67. Our Smart Value Score of 32/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 1.14, it sits in the distress. TTM revenue stands at $451.36M. with profit margins at -14.70%. Our DCF model estimates intrinsic value at $45.01.
Frequently asked questions
What is Tarsus Pharmaceuticals Inc's stock price?
Tarsus Pharmaceuticals Inc (TARS) trades at $60.67.
Is Tarsus Pharmaceuticals Inc overvalued?
Smart Value Score 32/100 (Grade F, Strong Sell). DCF value $45.01.
What is the price target of Tarsus Pharmaceuticals Inc (TARS)?
The analyst target price is $94.22, representing +55.3% upside from the current price of $60.67.
What is the intrinsic value of Tarsus Pharmaceuticals Inc (TARS)?
Based on our DCF model, intrinsic value is $45.01, a -45.3% margin of safety versus $60.67.
What is Tarsus Pharmaceuticals Inc's revenue?
TTM revenue is $451.36M.
Piotroski F-Score?
4/9 — moderate financial health.
Altman Z-Score?
1.14 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio5.78x
ROE-23.40%
Beta0.63
50D MA$68.97
200D MA$65.88
Shares out0.04B
Float0.03B
Short ratio—
Avg volume0.6M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—